Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform

Cellix Ltd., an international provider of microfluidic systems in the emerging field of nano-lifesciences, announced today its worldwide launch of the VenaFlux Platform. The VenaFlux Platform, the first semi-automated, high throughput microfluidic cell-based assay system, measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. The system thereby offers scientists an important and unique tool for drug discovery. The VenaFlux Platform is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.

Using the VenaFlux Platform, scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.

“Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies,” said Vivienne Williams, CEO of Cellix Ltd. “Our VenaFlux Platform accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.

Cellix’ technology provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. “To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix’ technology to characterize drug effects,” commented Ms. Williams.